Should we screen blood products for hepatitis e virus RNA ?

The Lancet

Volumn 383, Issue 9913, 2014, Pages 218-

  Féray, Cyrille ^a   Pawlotsky, Jean Michel ^a   Roque Afonso, Anne Marie ^b   Samuel, Didier ^b   Dhumeaux, Daniel ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; BIOCHEMICAL MARKER; HEPATITIS E VACCINE; IMMUNOGLOBULIN M; RIBAVIRIN; STEROID;

BLOOD; BLOOD EXAMINATION; BLOOD TRANSFUSION; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; ACUTE HEPATITIS; DISEASE CARRIER; ENDEMIC DISEASE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; LIVER INJURY; NEUROLOGICAL COMPLICATION; PREVALENCE; SCREENING;

EID: 84892576844     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60072-6     Document Type: Letter

References (5)

1. Reyes GR, Purdy MA, Kim JP, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990; 247: 1335-39.
2. Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy. Semin Liver Dis 2013; 33: 62-70.
3. Kamar N, Izopet J, Cintas P, et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am J Transplant 2010; 10: 1321-24.
4. Coilly A, Haim-Boukobza S, Roche B, et al. Posttransplantation hepatitis E: transfusion-transmitted hepatitis rising from the ashes. Transplantation 2013; 96: e4-6.
5. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.